Evotec, Bayer partner in kidney disease

Evotec AG (Xetra:EVT) and Bayer AG (Xetra:BAYN) began a five-year collaboration to develop treatments for kidney diseases, including chronic kidney disease in diabetes patients.

Bayer will pay EUR 14 million ($15.6 million) over five years for exclusive access to Evotec's CureNephron target pipeline and undisclosed Evotec candidates. Evotech is eligible for more than EUR 300 million ($334.8 million) in development and sales milestones, plus tiered double-digit royalties. ...